Close

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences Mar 1, 2022 04:01PM
Needham & Company Reiterates Neurocrine (NBIX) at Hold, "Love Execution on Ingrezza" but Cautious on Future Pipeline Readouts Feb 14, 2022 05:51AM
Needham & Company Reiterates Hold on Neurocrine (NBIX), Calls Earnings Uneventful, Does Not Expect Big Move in Stock Feb 11, 2022 08:19AM
Neurocrine Biosciences (NBIX) Earnings Preview by Needham: Focus on Ingrezza Growth and Pipeline Feb 1, 2022 06:24AM
Neurocrine Biosciences (NBIX) Stock to Downtick in Light of Sales Miss, Needs More Growth Visibility - Needham Jan 7, 2022 06:22AM


Sep 22, 2021 04:11PM Needham & Company Assumes Neurocrine Bio. (NBIX) at Hold
Dec 23, 2020 08:56AM Pre-Open Stock Movers 12/23: (OCGN) (UAVS) (SUPN) (CLNE) (CLRB) (FUBO) (NKLA) (more...)
Aug 28, 2019 06:52AM Companies with NDRs 08/28
Jan 24, 2019 06:52AM Needham & Company Downgrades Neurocrine Bio. (NBIX) to Hold
Dec 12, 2018 10:48AM Neurocrine Bio. (NBIX) PT Lowered to $104 at Needham & Company
Dec 12, 2018 10:43AM Neurocrine Biosciences (NBIX)
Aug 1, 2018 07:16AM Neurocrine Bio. (NBIX) PT Raised to $125 at Needham & Company
Mar 6, 2018 07:37AM Neurocrine Biosciences (NBIX): Thoughts After KOL Call On Endometriosis and Uterine Fibroids - Needham
Feb 22, 2018 06:39AM Neurocrine Bio. (NBIX) PT Raised to $110 at Needham & Company on Elagolix UF Phase 3 Data and Opicapone NDA Path
Jan 16, 2018 06:43AM Neurocrine Bio. (NBIX) PT Raised to $95 at Needham & Company on Strength of Ingrezza Launch
Nov 2, 2017 07:41AM Neurocrine Biosciences (NBIX): Strong Ingrezza Launch Continues - Needham
May 24, 2017 06:28AM Neurocrine Biosciences (NBIX): Cutting PT After Tourette Endpoint Miss - Needham
Apr 12, 2017 06:54AM Needham and Company Reiterates Buy Rating and $62 PT on Neurocrine Biosciences (NBIX); 'FDA Approves Ingrezza, Launch Moved up to May'
Mar 17, 2017 07:23AM Neurocrine Biosciences (NBIX): KOL Call Implies Ingrezza Approval in '17 - Needham
Feb 15, 2017 07:58AM Needham & Company Reiterates Buy Rating and $62 PT on Neurocrine Biosciences (NBIX) Ahead of 2017 Catalyst
Jan 6, 2017 07:44AM Needham & Company Remains Bullish on Neurocrine Biosciences (NBIX) Following FDA Announcement
Oct 18, 2016 07:01AM Needham & Company Starts Neurocrine Bio. (NBIX) at Buy
Jan 8, 2014 09:32AM Pre-Open Stock Movers 1/8: (PATH) (FRX) (MU) Higher; (TCS) (JCP) (TWTR) Lower (more...)
Sep 10, 2013 09:29AM Pre-Open Stock Movers 9/10: (INO) (FIVE) (NKE) Higher; (MODN) (NBIX) (CCXI) Lower (more...)
Sep 9, 2013 06:11PM After-Hours Stock Movers 9/9: (FIVE) (FLOW) (PANW) Higher; (NBIX) (MODN) (PBY) Lower (more...)